News | April 20, 2026
Eli Lilly flags counterfeit Mounjaro seizure in Gurugram
The company said it is supporting the ongoing investigation and reiterated its commitment to patient safety.
The company said it is supporting the ongoing investigation and reiterated its commitment to patient safety.
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The study evaluated asundexian (50 mg), a once-daily oral anticoagulant candidate, versus placebo—both given alongside standard antiplatelet therapy
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
Move amid evidence of widespread reporting gaps
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study
Highlights Mirvetuximab-based regimen promise
The approval clears the way for a US study at leading clinical centers to evaluate the safety and effectiveness of VDYNE’s system in patients
Subscribe To Our Newsletter & Stay Updated
